Cargando…

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study

BACKGROUND: In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deaths in a cohort of 796,072 insured subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paternina-Caicedo, Angel, Jit, Mark, Alvis-Guzmán, Nelson, Fernández, Juan Carlos, Hernández, José, Paz-Wilches, Justo Jesus, Rojas-Suarez, José, Dueñas-Castell, Carmelo, Alvis-Zakzuk, Nelson J., Smith, Adrian D., Hoz-Restrepo, Fernando De La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246705/ https://www.ncbi.nlm.nih.gov/pubmed/35791428 http://dx.doi.org/10.1016/j.lana.2022.100296

Ejemplares similares

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

PRS21 Quantifying the years of life lost due to COVID-19 in Colombia: preliminary estimates
por: Alvis-Zakzuk, N., et al.
Publicado: (2021)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Willingness to receive the COVID-19 vaccine in the population aged 80 years and older in Colombia 2021()
por: Alvis-Guzman, N., et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
por: Suah, Jing Lian, et al.
Publicado: (2022)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
por: Yavuz, Erdal, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
por: Masson, Letícia Carrijo, et al.
Publicado: (2023)

Effectiveness of a prevention program in the incidence of cardiovascular outcomes in a low-income population from Colombia: a real-world propensity score-matched cohort study
por: Miranda-Machado, Pablo, et al.
Publicado: (2020)

Disposición a recibir la vacuna contra COVID-19 en población de 80 y más años en Colombia 2021
por: Alvis-Guzman, N., et al.
Publicado: (2021)

Disposición a recibir la vacuna contra COVID-19 en población de 80 y más años en Colombia 2021
por: Alvis-Guzman, N., et al.
Publicado: (2022)

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
por: Clavero, Rene, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
por: Leung, Daniel, et al.
Publicado: (2022)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
por: Oliveira, Eduardo A., et al.
Publicado: (2023)

How Expensive Are Hospitalizations by COVID-19? Evidence From Colombia
por: Alvis-Zakzuk, Nelson J., et al.
Publicado: (2022)

Centers of Excellence Implementation for Treating Rheumatoid Arthritis in Colombia: A Cost-Analysis
por: Santos-Moreno, Pedro, et al.
Publicado: (2021)

EE319 Healthcare Resource Utilization and Direct Medical Costs Associated with Post COVID-19 Condition in Colombia, 2020-2021
por: Salcedo Mejía, F., et al.
Publicado: (2023)

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
por: Khong, Ka-Wa, et al.
Publicado: (2022)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
por: Sonmezer, Meliha Cagla, et al.
Publicado: (2022)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
por: Mirioglu, Safak, et al.
Publicado: (2023)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Is Colombia an example of successful containment of the 2020 COVID-19 pandemic? A critical analysis of the epidemiological data, March to July 2020
por: De la Hoz-Restrepo, Fernando, et al.
Publicado: (2020)

PNS14 Direct Medical Costs Related to COVID-19 in Colombia
por: Alvis-Zakzuk, N., et al.
Publicado: (2021)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m8ri793ldklgfd17fp2a19dck7